drugset
drugset / Trial / NCT01397929

An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors

NCT01397929 ↗

Phase 1/2 Completed 73 enrolled Basilea Pharmaceutica
RandomizedParallel-groupOpen-labelTreatment

Summary

First in human, open-label, sequential dose escalation and expansion study of intravenous BAL101553 in adult patients with advanced solid tumors.

Timeline

Start
2011-06
Primary completion
2016-01
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lisavanbulin Small molecule — Intravenous

Indications

No indication recorded.